SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-058118
Filing Date
2023-03-02
Accepted
2023-03-02 16:06:04
Documents
12
Period of Report
2023-02-28
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d447916d8k.htm   iXBRL 8-K 23418
  Complete submission text file 0001193125-23-058118.txt   140812

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA akba-20230228.xsd EX-101.SCH 2834
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20230228_lab.xml EX-101.LAB 17234
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20230228_pre.xml EX-101.PRE 10801
6 EXTRACTED XBRL INSTANCE DOCUMENT d447916d8k_htm.xml XML 3279
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 23698866
SIC: 2834 Pharmaceutical Preparations